Related Experiment Video

Updated: May 21, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment

Bruno Gori1, Serena Ricciardi, Alberto Fulvi

  • 1Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy. bruno.gori@yahoo.it

Future Oncology (London, England)
|June 1, 2012
PubMed

Insights

Oral antiangiogenic agents, including tyrosine kinase inhibitors, offer a promising targeted therapy for advanced non-small-cell lung cancer. These drugs represent a new class of treatments with a favorable safety profile for patients with poor prognoses.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small-cell lung cancer (NSCLC) is an aggressive malignancy with poor prognosis in advanced or metastatic stages.
  • Current standard first-line chemotherapy offers limited options for patients who progress.
  • Tumor angiogenesis, driven by disrupted angiogenic factor balance, is a critical process for cancer growth.

Purpose of the Study:

  • To review oral antiangiogenic agents for advanced non-small-cell lung cancer.
  • To focus on approved and clinically developing tyrosine kinase inhibitors (TKIs).
  • To highlight targeted therapies interfering with specific cancer cell signaling pathways.

Main Methods:

  • Review of scientific literature on antiangiogenic strategies in cancer therapy.
  • Focus on small molecule inhibitors targeting VEGF tyrosine kinase activity.
  • Analysis of approved and investigational oral antiangiogenic agents for NSCLC.

Main Results:

  • Angiogenesis inhibition is a validated anticancer therapeutic strategy.
  • Tyrosine kinase inhibitors are orally active small molecules with a good safety profile.
  • Several oral antiangiogenic agents are approved or in advanced development for NSCLC.

Conclusions:

  • Oral antiangiogenic TKIs represent a significant advancement in targeted therapy for advanced NSCLC.
  • These agents offer a new treatment avenue for patients with poor prognoses.
  • Further clinical development of these targeted therapies is ongoing.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...